VM
SYRE icon

VHCP Management’s Spyre Therapeutics SYRE Stock Holding History

VHCP Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$26K Hold
240
– – 0.03% 21
2016
Q3 		$38K Hold
240
– – 0.04% 24
2016
Q2 		$29K Buy
+240
New +$46K 0.03% 23

Other funds holding SYRE

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VHCP Management's SYRE Position: Q4 2016 in Review

VHCP Management held its Spyre Therapeutics (SYRE) position steady in Q4 2016 at 240 shares worth $26K. The position accounts for 0.03% of the portfolio, ranked #21.

VHCP Management first reported a position in SYRE in Q2 2016 and has held it in 3 quarters since. The position peaked at $38K in Q3 2016. 26 funds tracked by Wall St. Rank hold SYRE as of Q4 2016.

  • VHCP Management held 240 shares of Spyre Therapeutics worth $26K as of Q4 2016.
  • VHCP Management left its Spyre Therapeutics share count unchanged in Q4 2016.
  • Spyre Therapeutics made up 0.03% of VHCP Management's portfolio in Q4 2016, its #21 holding.
  • VHCP Management first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • VHCP Management's Spyre Therapeutics position peaked at $38K in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2016.

Based on VHCP Management's 13F filing for Q4 2016, filed 13 Feb 2017.